Results with Lifescozul™Brain Cancer
Introduction to the case
For LifEscozul Group, all patients are important, but when it comes to children, our doctors and specialists take extra care in each of their actions.
In the case we bring today, it is not only about a child, but also the desperation of a mother to find a solution to a disease that little by little was leaving the doctors with no options.
It has almost been a year since Matias has been with us, and the results have been fabulous.
Matías Hawasly Hoyos, Male, 5 and a half years old at the beginning of treatment with LifEscozul.
Asymptomatic, only inflammation of the left eye.
First week of July 2019.
Recurrent Cerebral Pineoblastoma.
Matias was diagnosed at the age of 3 and a half years with Pineoblastoma. He underwent the following treatments:
- Initially received subtotal surgery
- Adjuvant chemotherapy with exclusive chemotherapy (no radiotherapy initially) Head Start protocol.
- Consolidation with autologous bone marrow transplant in March 2018.
However none of this worked as he presented with local tumor relapse (November 2018) which was resolved with macroscopically completed surgical resection on November 14, 2018.
Subsequently, he received radiotherapy from December 27, 2018 to February 13, 2019. Again it was in vain, since in the MRI performed in May 2019, it was observed that the tumor returned.
In response, the treating physicians in his country indicated that there was no other treatment option to offer.
And he was sent home.
The LifEscozul (escozul, blue scorpion venom) Medical Team, led by Dr. Aaron Sarmiento, then proceeded to analyze what real possibilities Matias had with this treatment.
Knowing the success we have had in children, we proceeded to design a dose with progressive increases and exhaustive medical surveillance.
However, we were cautious so as not to create false expectations in Matías' family.
In July 2019, Matias began treatment with LifEscozul (escozul, blue scorpion venom) the most advanced formulation ever made with blue scorpion venom.
Evolution with LifEscozul™ and actual results
During the treatment period, Matias' mother has maintained frequent communication with the LifEscozul medical team, which has allowed her to closely follow Matias' evolution and his response to the treatment.
Two weeks later:
About 2 weeks after starting treatment with LifEscozul, Matias underwent a control MRI, where it was observed that tumor growth was maintained with dimensions of 8x6mm.
At 3 months:
At the next control in October 2019, after 3 months on treatment with LifEscozul alone, no new lesions or metastases were identified in the MRI.
At 5 months:
A new MRI was performed in December which showed that the tumor had disappeared.
May 8, 2020:
The most recent MRI with contrast, performed on May 8, 2020, once again establishes that there is no evidence of tumor residue or recurrence.
In the words of Matías' mother:
... "the treating oncologist says that she sees the child very well, asymptomatic, that he has not yet been declared free of the disease because he must continue to be supervised for another year every 3 months with a skull MRI, but that he is doing very well, he has already been one year without treatment only with LifEscozul (escozul, blue scorpion venom) and is doing very well"...
Matias continues treatment with LifEscozul with periodic dose readjustments.
We hope that these results will be sustained over time and that Matias can be declared cancer-free in the future.
When Matias came to us, his medical options were to wait. No proposed treatment had succeeded in eliminating the tumor in his brain, and each time the cancer returned with increasing force.
However, Matias' mother decided to try LifEscozul (escozul, blue scorpion venom).
Today, Matias is cancer-free.
As we always say, it is important to note that it is not possible to generalize any results with LifEscozul to avoid creating false expectations in people, as cancer is a very complex disease where a single product cannot be effective in all.
But the success we have obtained in more than 3000 people is only possible due to the joint work and constant communication with patients that allow us to keep LifEscozul doses as personalized as possible, avoiding tumor adaptation.
It is also important to say that all the medical information of the case is available for consultation, as well as contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.
In 2016 Hector was diagnosed with a grade I bladder carcinoma. To treat his disease they proposed chemotherapy and BCG immunotherapy, but Hector refused both treatments. View more